Long‐Bin Jeng

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson, Shukui Qin, Joong‐Won Park et al. · Journal of Clinical Oncology · 2013 · 775 citations · Full text

Medicine, Oncology, Pharmacology +14

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Reoperative Thyroid Surgery

Tzu‐Chieh Chao, Long‐Bin Jeng, Jen‐Der Lin et al. · World Journal of Surgery · 1997 · 157 citations

Medicine, Oncology, Surgery +15

Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage

Chun‐Jen Liu, Po‐Huang Lee, Deng‐Yn Lin et al. · Journal of Hepatology · 2009 · 153 citations

Medicine, Oncology, Pharmacology +9